Skip to main content

Advertisement

SpringerLink
Log in

Reduction in urinary tract infections in patients treated with fecal microbiota transplantation for recurrent Clostridioides difficile infection

  • Brief Report
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

We performed an updated study to investigate the rates of urinary tract infections (UTIs) in patients with recurrent Clostridioides difficile infection (CDI) who received fecal microbiota transplantation (FMT) for CDI. We found a significant reduction in number of UTIs after FMT compared to patients who received antibiotics for CDI treatment. After FMT, we also observed a trend towards reduction of antibiotic resistance in organisms causing UTI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

The datasets generated during and/or analyzed during the current study are not publicly available due to patient privacy but are available from the corresponding author on reasonable request.

References

  1. Waller TA, Pantin SAL, Yenior AL, Pujalte GGA (2018) Urinary tract infection antibiotic resistance in the United States. Prim Care 45(3):455–466

    Article  PubMed  Google Scholar 

  2. Morand A, Cornu F, Dufour JC, Tsimaratos M, Lagier JC, Raoult D (2019) Human bacterial repertoire of the urinary tract: a potential paradigm shift. J Clin Microbiol 57(3):e00675-18

    Article  PubMed  PubMed Central  Google Scholar 

  3. Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, Iqbal TH (2017) Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 46(5):479–493

    Article  CAS  PubMed  Google Scholar 

  4. Ramos-Martinez A, Martinez-Ruiz R, Munez-Rubio E, Valencia-Alijo A, Ferre-Aracil C, Vera-Mendoza MI (2020) Effect of faecal microbiota transplantation on recurrent urinary tract infection in a patient with long-term suprapubic urinary catheter. J Hosp Infect 105(2):332–333

    Article  CAS  PubMed  Google Scholar 

  5. Wang T, Kraft CS, Woodworth MH, Dhere T, Eaton ME (2018) Fecal microbiota transplant for refractory Clostridium difficile infection interrupts 25-year history of recurrent urinary tract infections. Open Forum. Infect Dis 5(2):ofy016

    Google Scholar 

  6. Tariq R, Pardi DS, Tosh PK, Walker RC, Razonable RR, Khanna S (2017) Fecal microbiota transplantation for recurrent Clostridium difficile infection reduces recurrent urinary tract infection frequency. Clin Infect Dis 65(10):1745–1747

    Article  CAS  PubMed  Google Scholar 

  7. Tariq R, Weatherly R, Kammer P, Pardi DS, Khanna S (2018) Donor screening experience for fecal microbiota transplantation in patients with recurrent C. difficile infection. J Clin Gastroenterol 52(2):146–150

    Article  PubMed  Google Scholar 

  8. Lagier JC, Million M, Fournier PE, Brouqui P, Raoult D (2015) Faecal microbiota transplantation for stool decolonization of OXA-48 carbapenemase-producing Klebsiella pneumoniae. J Hosp Infect 90(2):173–174

    Article  CAS  PubMed  Google Scholar 

  9. Bier N, Hanson B, Jiang ZD, DuPont HL, Arias CA, Miller WR (2023) A case of successful treatment of recurrent urinary tract infection by extended-spectrum beta-lactamase producing Klebsiella pneumoniae using oral lyophilized fecal microbiota transplant. Microb Drug Resist 29(1):34–38

    Article  CAS  PubMed  Google Scholar 

  10. Jeney SES, Lane F, Oliver A, Whiteson K, Dutta S (2020) Fecal microbiota transplantation for the treatment of refractory recurrent urinary tract infection. Obstet Gynecol 136(4):771–773

    Article  PubMed  PubMed Central  Google Scholar 

  11. Magruder M, Sholi AN, Gong C, Zhang L, Edusei E, Huang J, Albakry S, Satlin MJ, Westblade LF, Crawford C, Dadhania DM, Lubetzky M, Taur Y, Littman E, Ling L, Burnham P, De Vlaminck I, Pamer E, Suthanthiran M, Lee JR (2019) Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat Commun 10(1):5521

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kamada N, Chen GY, Inohara N, Nunez G (2013) Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 14(7):685–690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wolfensberger A, Kuster SP, Marchesi M, Zbinden R, Hombach M (2019) The effect of varying multidrug-resistence (MDR) definitions on rates of MDR gram-negative rods. Antimicrob Resist Infect Control 8(1):1–9

    Article  Google Scholar 

Download references

Funding

National Institute of Diabetes and Digestive and Kidney Diseases, Grant/Award Number: DK07198.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA

    Raseen Tariq, Darrell S. Pardi & Sahil Khanna

  2. Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA

    Pritish K. Tosh

Authors
  1. Raseen Tariq
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pritish K. Tosh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Darrell S. Pardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sahil Khanna
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

R.T.: conceptualization, analysis, writing original draft; P.K.T.: reviewing and editing; D.S.P.: reviewing and editing; S.K.: conceptualization, analysis, reviewing and editing.

Corresponding author

Correspondence to Sahil Khanna.

Ethics declarations

Ethics approval

This is an observational study. The study was approved from Institutional Review Board at Mayo Clinic and has confirmed that no ethical approval is required.

Conflict of interest

SK receives research support from Rebioitx/Ferring, Vedanta, Finch, Seres, and Pfizer. SK serves as a consultant for ProbioTech, Takeda, Niche, and Immuron. DSP has grant funding from Pfizer, Vedanta, Seres, Finch, Applied Molecular Transport, and Takeda. He has consulted for Vedanta, Seres, AbbVie, Immunic, and Otsuka.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

ESM 1

(DOCX 15 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tariq, R., Tosh, P.K., Pardi, D.S. et al. Reduction in urinary tract infections in patients treated with fecal microbiota transplantation for recurrent Clostridioides difficile infection. Eur J Clin Microbiol Infect Dis 42, 1037–1041 (2023). https://doi.org/10.1007/s10096-023-04635-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-023-04635-4

Search

Navigation